7.63
前日終値:
$7.525
開ける:
$7.57
24時間の取引高:
11,545
Relative Volume:
0.15
時価総額:
$4.48M
収益:
$49,300
当期純損益:
$-6.27M
株価収益率:
-0.8394
EPS:
-9.09
ネットキャッシュフロー:
$-5.38M
1週間 パフォーマンス:
+12.35%
1か月 パフォーマンス:
+17.90%
6か月 パフォーマンス:
+96.50%
1年 パフォーマンス:
-2.76%
Aclarion Inc Stock (ACON) Company Profile
ACON を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ACON
Aclarion Inc
|
7.63 | 4.48M | 49,300 | -6.27M | -5.38M | -9.09 |
![]()
VEEV
Veeva Systems Inc
|
282.54 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
59.45 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
58.69 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
103.03 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
39.51 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Aclarion Inc (ACON) 最新ニュース
Contrasting Aclarion (NASDAQ:ACON) and Aeon Global Health (OTCMKTS:AGHC) - Defense World
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site - Ortho Spine News
Aclarion (ACON) Expands CLARITY Trial with University of Miami H - GuruFocus
Aclarion Inc. Announces UHealth and University of Miami as New Site for CLARITY Clinical Trial Evaluating Nociscan for Chronic Low Back Pain - Nasdaq
Aclarion (NASDAQ:ACON) Upgraded by Wall Street Zen to Hold Rating - Defense World
Aclarion stock price target cut to $20 at Ascendiant Capital - Investing.com Australia
Aclarion stock price target cut to $20 at Ascendiant Capital By Investing.com - Investing.com India
Aclarion, Inc. (NASDAQ:ACON) Sees Large Drop in Short Interest - Defense World
Aclarion (NASDAQ:ACON) Trading Down 1.2% – Here’s Why - Defense World
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site - Ortho Spine News
USC Medical Center Joins Groundbreaking AI Trial to Revolutionize Chronic Back Pain Diagnosis - Stock Titan
Aclarion, Inc. SEC 10-Q Report - TradingView
Aclarion (ACON) Expands CLARITY Trial with Texas Back Institute - GuruFocus
Aclarion Announces Texas Back Institute as New CLARITY Trial Site - Ortho Spine News
Aclarion announces Texas Back Insitute as new CLARITY trial site - TipRanks
Aclarion Inc. Partners with Texas Back Institute for CLARITY Clinical Trial to Enhance Chronic Low Back Pain Treatment - Nasdaq
History Says Now Is the Time to Buy Nvidia Stock - The Globe and Mail
Aclarion Welcomes Advocate Health as CLARITY Trial Site - Ortho Spine News
Major Breakthrough: Advocate Health to Test AI-Powered Spine Pain Diagnostic in 300-Patient Trial - Stock Titan
Aclarion secures funding for pivotal CLARITY trial - MSN
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana - Ortho Spine News
Aclarion (ACON) Partners with Louisiana Spine Institute to Expan - GuruFocus
Aclarion announces agreement with the Spine Institute of Louisiana - TipRanks
Aclarion Expands Nociscan Access with Commercial Agreement at Spine Institute of Louisiana - Nasdaq
Revolutionary Spine Pain Technology Nociscan Achieves 97% Success Rate, Expands to 17 Medical Centers - Stock Titan
Aclarion stock hits 52-week low at $7.25 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion stock hits 52-week low at $7.25 amid steep annual decline - Investing.com
Aclarion, Inc. (NASDAQ:ACON) Short Interest Update - Defense World
Aclarion Inc Files For Mixed Shelf Of Up To $150 MlnSEC Filing - marketscreener.com
Aclarion Releases Updated Investor Presentation at Showcase - TipRanks
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - The Manila Times
Aclarion, Inc. to Present at Planet MicroCap Showcase: VEGAS 2025 on Chronic Low Back Pain Solutions - Nasdaq
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet ... - Bluefield Daily Telegraph
Aclarion's Revolutionary AI Approach to Chronic Back Pain: New Investor Strategy Revealed at MicroCap Vegas - Stock Titan
3 Reasons to Buy Amazon Stock Like There's No Tomorrow - The Globe and Mail
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis - Ortho Spine News
Aclarion's Nociscan Demonstrates Cost-Effectiveness and Improved Surgical Success Compared to Provocative Discography - Nasdaq
New Research: AI-Powered Spine Technology Cuts Patient Costs by $1,712, Boosts Surgery Success 10% - Stock Titan
NOCISCAN touted as lumbar pain diagnostic advance - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub - The Manila Times
Aclarion, Inc. SEC 10-K Report - TradingView
Aclarion stock hits 52-week low at $9.68 amid steep annual decline - Investing.com Canada
Aclarion stock hits 52-week low at $9.68 amid steep annual decline By Investing.com - Investing.com South Africa
Aclarion Inc (ACON) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):